



"In our efforts to secure a licensing partner for China, we highly valued Lingmed's support on our TCR technology platform, which enabled us to have an efficient partnering progress and a more structured value proposition for our assets/platform to fit into the local market"

Rolf Kalhammer, Ph.D., VP of Business
Development

Linkedbio Success case license agreement support to Medigene

- Sell side mandate : Medigene AG (Europe)
- Product: TCR-T cell therapy portfolio for solid tumors
- Challenges: Find a licensing partner for TCR-T cell therapy portfolio in China
- Lingmed activities: Rewrote TCR- T cell proposition to make it more attractive to potential partners, established contact with various Chinese pharma companies through Lingmed's connections and negotiated competitive term sheets
- Territory: Exclusive license agreement with Cytovant Sciences in Greater China, South Korea and Japan

medigene
innovative immunotherapies



Cytovant
CELL THERAPIES
鸿声医药

POTENTIAL DEAL SIZE: USD 10 million
upfront plus development, regulatory, sales
milestones and tiered up to double-digit
royalties